•
Sep 30, 2023
ANI Pharmaceuticals Q3 2023 Earnings Report
ANI Pharmaceuticals achieved record financial results driven by Rare Disease, Generics and Established Brands businesses.
Key Takeaways
ANI Pharmaceuticals reported strong Q3 2023 results, with a 57% increase in revenues to $132 million and a 119% increase in diluted non-GAAP EPS to $1.27. The company's growth was driven by its Rare Disease business, Generics, and Established Brands.
Cortrophin Gel demonstrated strong momentum with record new patient starts and cases initiated.
The R&D organization delivered five new product launches and filed three new ANDAs and two 505(b)(2) NDA applications.
The company continued responding to pharmaceutical shortages through operational excellence and its U.S. manufacturing footprint.
Full year 2023 guidance was raised for the third quarter in a row.
ANI Pharmaceuticals
ANI Pharmaceuticals
Forward Guidance
ANI Pharmaceuticals raised its full year 2023 guidance for the third quarter in a row.